Evolving '-omics' technologies in the drug development process.

Area of Science:

• Biomedicine
• Pharmacology
• Systems Biology

Background:

• '-omics' technologies enable large-scale, high-throughput biomolecule activity monitoring, accelerating drug discovery.
• Technological advancements have improved reproducibility and sensitivity for precise pathological process deciphering.
• Strict standardization and expert requirements necessitate dedicated core facilities for '-omics' implementation.

Purpose of the Study:

• To review the current state of mainstream '-omics' technologies in drug discovery.
• To discuss the limitations and future perspectives of these '-omics' approaches.
• To highlight the role of systems biology in overcoming drug discovery bottlenecks.

Main Methods:

• Review of current '-omics' technologies (genomics, proteomics, metabolomics, etc.).
• Integration of '-omics' data with pathway analysis, bioinformatics, and mathematical modeling.
• Exploration of systems biology frameworks for target identification.

Main Results:

• '-Omics' technologies offer powerful tools for drug discovery but face challenges in standardization and resource allocation.
• Systems biology provides an integrated approach to address bottlenecks in target identification and validation.
• Future applications involve enhanced pathway-oriented '-omics' integration for precision medicine.

Conclusions:

• Systems biology, by integrating '-omics' data with other analyses, is crucial for efficient drug discovery.
• Addressing standardization and resource challenges will enhance the utility of '-omics' in identifying disease-relevant drug targets.
• Continued advancements in '-omics' and systems biology promise to revolutionize therapeutic development.